Asset Details
Do you wish to reserve the book?
Population pharmacokinetics modelling for clinical dose adjustment of carboplatin in dogs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Population pharmacokinetics modelling for clinical dose adjustment of carboplatin in dogs
Do you wish to request the book?
Population pharmacokinetics modelling for clinical dose adjustment of carboplatin in dogs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Population pharmacokinetics modelling for clinical dose adjustment of carboplatin in dogs
2024
Overview
Background
Carboplatin is a human chemotherapeutic agent which is frequently used in dogs for the management of solid tumors. In human patient, its dosage is adjusted carefully, based on the creatinine clearance computation. In dogs however, the pharmacokinetics of carboplatin is poorly known and the dose 300 mg/m2 is based mostly on empirical data. Here, we aimed at characterizing the pharmacokinetics of carboplatin and determined the influence of several covariates, including creatinine plasma concentration and neutering status, in dogs, and used this model to predict myelotoxicity.
Results
Sixteen client owned dogs were included after carboplatin administration (300 mg/m
2
). For each animals, three to four plasma samples were collected and free plasma concentration of carboplatin was determined by HPLC/MS and analysed using Monolix® software with Non-linear mixed effect modelling. A mono-compartmental model best described the plasma concentration of carboplatin with log plasma creatinine concentration and sterilization status as covariates. After adjustment with the covariates, median population clearance was 3.62 [3.15 – 4.12] L/h/kg and volume of distribution was 3.93 [3.84 – 4.14] L/kg. The application of this model in 14 additional dogs demonstrates that individual drug exposure (model-predicted Area Under the Curve) predicted thrombocyte blood reduction (Pearson coefficient
r
2
= 0.73,
p
= 0.002) better than dose after 14 days following administration of carboplatin.
Conclusion
Based on our results, plasma creatinine concentration and the sterilization status are relevant explanatory covariates for the pharmacokinetics variability of carboplatin in client owned dogs. Dose adjustment based on these parameters could represent a promising strategy for minimizing thrombocyte toxicity.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - blood
/ Antineoplastic Agents - pharmacokinetics
/ Carboplatin - administration & dosage
/ Carboplatin - pharmacokinetics
/ Carboplatin - therapeutic use
/ Computer-generated environments
/ Diseases
/ Dogs
/ drugs
/ Female
/ humans
/ Male
/ Medicine
/ Methods
/ patients
/ Plasma
/ Software
/ Toxicity
/ Veterinary Medicine/Veterinary Science
/ Zoology
